AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01792908 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: The KT used was Kinesiology Tape® of 5 cm and it was applied according to Kase protocol (Kase K). The first layer of tape consisted of a single strip placed over the anterior talofibular ligament from insertion to origin, with a 50% tension, except the two-centimetre proximal and distal ends, applied with no tension. The same procedure was repeated for the calcaneofibular ligament and posterior talofibular ligament
Study NCT04582617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cocoa Extract Placebo
Description: Cocoa extract placebo
Study NCT04582617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin
Description: Multivitamin
Study NCT04582617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Multivitamin placebo
Description: Multivitamin placebo
Study NCT04582617 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Multivitamin placebo
Description: Multivitamin placebo
Study NCT02395822 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15
Description: Preparative Regimen:~Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (if \< 4 months from prior transplant, omit day -4 dose)~IL-15 Activated Donor NK Cells:~The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be activated by overnight incubation with10 ng/ml IL-15 under GMP conditions and infused on day 0.~IL-15 to Facilitate NK Cell Survival and Expansion:~IL-15 at 2 mcg/kg subcutaneously (SC) beginning day +1, once a day for 5 days followed by a 2 day rest, and then once a day for 5 days for 10 doses total
Study NCT02494024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose C2N-8E12
Description: C2N-8E12 is a humanized recombinant anti-human tau antibody.
Study NCT02494024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single dose placebo
Description: Subjects will be block randomized to receive a single dose of C2N-8E12 or placebo in two blocks of 4 subjects (3:1, C2N-8E12:placebo) per cohort.
Study NCT02819128 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Swabs skin, pharyngeal, and blood sample
Description: Collection of one blood sample with a volume of 10 mL (2 tubes of blood 5 mL ) and 2 swabs ( throat and skin ).
Study NCT02819128 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of body lice
Description: For the subjects infested with body lice , if they want, their underwear will be recovered and sent to the laboratory to measure the resistance to permethrin.
Study NCT00537836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 86-5310 (ZK 283197)
Description: 3 mg (3 x 1 mg tablet) or 2 mg (2 x 1 mg tablet) ZK 283197 in respective treatment group, once daily p.o. over 8 weeks
Study NCT00537836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily p.o. over 8 weeks
Study NCT00537836 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17ß-estradiol
Description: 1 mg (2 x 0.5 mg tablet) 17ß-estradiol, once daily p.o. over 8 weeks
Study NCT01975441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine 6mg/kg
Study NCT01975441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine 6mg/kg
Study NCT01975441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole 400mg
Study NCT01975441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole 400mg
Study NCT01975441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Ivermectin 200 mcg/kg
Study NCT02196129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinbaro-3
Description: 1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
Study NCT02196129 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hwangryun
Description: 1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
Study NCT00745602 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non-invasive testing
Description: non-invasive tests including Transcranial Doppler ultrasound (TCD), manual cuff blood pressure (BP), beat to beat BP monitoring by a Portapress monitor, and respiratory tidal CO2
Study NCT03036943 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Fluciclovine
Description: Fluciclovine (18F) PET/CT scan completed >= 48 hours prior to surgical resection for breast cancer
Study NCT01530919 — intervention group
Intervention type: PROCEDURE
Intervention: Minimally invasive radioguided parathyroidectomy
Description: After the patient is prepared for surgery and under local anesthesia, the initial incision by the surgeon will be 2-3 cm. The surgeon will dissect in the designated quadrant until the parathyroid gland is identified.
Study NCT01928849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: Intervention patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital.
Study NCT01928849 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cherry Syrup
Description: Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.
Study NCT01934179 — intervention group
Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Undergo blood sample collection
Study NCT01934179 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01934179 — intervention group
Intervention type: OTHER
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02065557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneous (SC) injection
Study NCT02065557 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Adalimumab
Description: Subcutaneous (SC) injection
Study NCT02065557 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) injection
Study NCT02065557 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous (SC) injection
Study NCT01799694 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inject of Autologous Adipose-derived stem cells
Description: Inject in muscle of autologous adipose derived stem cells
Study NCT03025204 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enamel Matrix Proteins
Description: EMD is composed of different proteins, 90% of which are amelogenins, which has the capacity to induce processes involved in the regeneration of periodontal tissues in a manner similar to normal tissue development (48). Several clinical and animal model studies have demonstrated the use of enamel matrix-derived proteins in regenerative periodontal procedures for the formation of a new periodontium.
Study NCT03025204 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Enamel Matrix Proteins
Description: EMD is composed of different proteins, 90% of which are amelogenins, which has the capacity to induce processes involved in the regeneration of periodontal tissues in a manner similar to normal tissue development (48). Several clinical and animal model studies have demonstrated the use of enamel matrix-derived proteins in regenerative periodontal procedures for the formation of a new periodontium.
Study NCT03025204 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Flap Debridement
Description: After administration of local anesthetics, full-thickness flaps will be raised in order to access all defect faces. Sulcular incisions will be performed extending to mesial and distal adjacent teeth, including the entire papilla in the flap. No relaxing incisions will be performed. All granulation tissue will then be carefully removed, and subsequently scaling and root planing will be performed. The surgical area will be irrigated with 0.9% saline and carefully inspected to ensure that all steps have been satisfactorily performed until then.
Study NCT03025204 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open Flap Debridement
Description: After administration of local anesthetics, full-thickness flaps will be raised in order to access all defect faces. Sulcular incisions will be performed extending to mesial and distal adjacent teeth, including the entire papilla in the flap. No relaxing incisions will be performed. All granulation tissue will then be carefully removed, and subsequently scaling and root planing will be performed. The surgical area will be irrigated with 0.9% saline and carefully inspected to ensure that all steps have been satisfactorily performed until then.
Study NCT06135038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Suprascapular nerve block with physical therapy
Description: Suprascapular nerve block was applied to the relevant shoulder area of all patients before treatment. Afterwards, a physical therapy program (5 days a week for 3 weeks, a total of 15 sessions) was applied, including 20 minutes of hot pack at 60°C, 20 minutes of conventional TENS at 80 Hz and US at 3 MHz frequency and 1.5 watt/cm2 intensity.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist.
Study NCT06135038 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 2 Physical therapy
Description: A physical therapy program (5 days a week for 3 weeks, a total of 15 sessions), including a hot pack at 60 ° C for 20 minutes, conventional TENS at 80 Hz for 20 minutes and US at 3 MHz frequency and an intensity of 1.5 watts / cm2, was applied to the relevant shoulder area of all patients.~After physical therapy, all the participants received therapeutic exercise program (3 sets of 10 reps with 3- minute intervals between the sets) consisting of active-assisted ROM, passive stretching and Codman exercises for their shoulder joint for 30 minutes in accompany with a physiotherapist.
Study NCT02760303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be the thought-emotion-behavior linkages as outlined by cognitive-behavioral theory. Activities will illustrate how thoughts affect emotions and behaviors, the application of these activities to current stressors, and strategies to apply these new skills to future stressors.
Study NCT02760303 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction
Description: Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be understanding how to gain control over one's thoughts and feelings using relaxation, meditation, and other mindfulness-based techniques. Activities will focus on the instruction and practice of mindfulness techniques, such as meditation and yoga, and the application of these practices to everyday activities.
Study NCT02760303 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Support and Education
Description: Participants will attend group therapy sessions, once a week for 9 weeks. Participants will receive diabetes education via a support group format. The focus of these sessions will be peer group social support and non-adherence diabetes education topics (e.g., emergency preparedness, smoking and diabetes).
Study NCT03613870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PermeaDerm
Description: Wound treatment with PermeaDerm
Study NCT03613870 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex Ag
Description: Wound treatment with Mepilex Ag
Study NCT03323762 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Conditioning (RIC)
Description: The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes
Study NCT01116531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Initial dose of oral tramadol (depottabl Tramal retard, Orionpharma, Finland) will be 100mg once daily. If the subject is currently on opioid treatment with codeine, tramadol or buprenorphine, the opioid treatment will be stopped, and an equal dose of tramadol will be used as the initial dose. The dose will be titrated on visits V2 and V3 based on the adequacy of pain relief and tolerability. If pain intensity ≥ 4 on a numeric rating scale of 0-10 during V2 and V3 and tramadol is well tolerated, the daily dose will be increased by 100mg. The maximum daily dose of 400 mg tramadol will not be exceeded. If the subject does not tolerate the initial dose of tramadol, he/she will be dropped out of the study and replaced by another patient.
Study NCT01116531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: The initial dose of duloxetine (Cymbalta, Eli Lilly, USA) will be 30mg once daily. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is \< 4 on a scale of 0-10, the dose of duloxetine dose will be 30mg daily throughout the study. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and duloxetine is well tolerated, the daily dose will be increased to 60mg once daily. If the subject does not tolerate the initial dose of duloxetine, he/she will be dropped out of the study and replaced by another patient.
Study NCT01116531 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: The initial dose of pregabalin (Lyrica, Pfizer, USA) will be 75mg twice a day. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is \< 4 on a scale of 0-10, the initial dose of pregabalin dose will be continued. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and pregabalin is well tolerated, the daily dose will be increased to 150mg twice a day. If the subject does not tolerate the initial dose of pregabalin, he/she will be dropped out of the study and replaced by another patient.
Study NCT03823625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab
Description: Nivolumab will be administered at the standard dose of 360 mg every 3 weeks. Ipilimumab will be administered at the dose of 1 mg/kg every 6 weeks.
Study NCT03823625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy plus Nivolumab
Description: Nivolumab will be administered at the standard dose of 360 mg every 3 weeks.~Platinum-based chemotherapy will be chosen by the investigator among the following regimens:~* Cisplatin 80 mg/mq iv day 1 and Gemcitabine 1250 mg/mq iv days 1 and 8 every 21 days;~* Carboplatin AUC 5 iv day 1 and Gemcitabine 1000 mg/mq iv days 1 and 8 iv every 21 days;~* Carboplatin AUC 6 iv day 1 and paclitaxel 200 mg/mq iv day 1 every 21 days.
Study NCT01462942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide/Formoterol Fumarate
Description: Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose (400/6 μg), twice per day
Study NCT01462942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide/Formoterol Fumarate
Description: Inhaled Aclidinium/formoterol FDC high dose (400/12 μg), twice per day
Study NCT01462942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium Bromide
Description: Inhaled Aclidinium 400 μg, twice per day
Study NCT01462942 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inhaled dose-matched placebo, twice per day
Study NCT01462942 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate
Description: Inhaled Formoterol 12 μg, twice per day
Study NCT04510168 — intervention group
Intervention type: DRUG
Intervention: 11C-ER176
Description: PET imaging to measure 18kDa translocator protein; target imaging dose of up to 20 millicurie (mCi)
Study NCT04510168 — intervention group
Intervention type: DRUG
Intervention: [F-18]MK-6240
Description: PET imaging to measure tau; target imaging dose of 4 to 5 mCi
Study NCT04510168 — intervention group
Intervention type: DRUG
Intervention: Florbetaben
Description: PET radioligand that binds to amyloid plaques; target-imaging dose of up to 8.1 mCi
Study NCT04510168 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Brain MRI
Study NCT03565289 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sample collection
Description: During a routine blood draw an additional tube of blood will be taken for the study.
Study NCT02246777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ex-PRESS® Glaucoma Filtration Device, Model P50PL
Study NCT03644732 — intervention group
Intervention type: PROCEDURE
Intervention: SEEG Group
Description: Visual and quantitative SEEG signal analysis. As available, collection of behavioral and neuropsychological postsurgical data
Study NCT01027845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK1024850A
Description: Intramuscular injection, 4 doses
Study NCT01027845 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTPa
Description: Subcutaneous injection, 4 doses
Study NCT01027845 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTPa
Description: Subcutaneous injection, 4 doses
Study NCT03749200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Obemat2.0 therapy
Study NCT03749200 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular practise in primary care
Study NCT02022917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/ Kg (from post-op cycle 2) intravenous infusion for 30 minutes in a 21 days' cycle for at least three cycles (best to 6 cycles) followed by 3-weekly maintenance bevacizumab 15 mg/ Kg intravenous infusion for 17 cycles.
Study NCT02420574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole BENDEX
Description: randomized clinical trial with 2 parallel arms
Study NCT02420574 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: albendazole OVIS
Study NCT00909974 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: UNIMMAP - multiple micronutrients
Description: Daily supplementation of one UNIMMAP tablet~multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
Study NCT00909974 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplement enriched with multiple micronutrients
Description: One dose of 72g per day during whole pregnancy~Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
Study NCT03742596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Formula Capsule
Description: The Probiotic will be coded in a specific label by a researcher. The patient will receive 2 bottles of the drug every 2 weeks and will be followed weekly for 7 weeks.
Study NCT03742596 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Control
Description: The Placebos will be coded in a specific label by a researcher.
Study NCT01189266 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo 3D conformal radiation therapy
Study NCT01189266 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo intensity-modulated radiation therapy
Study NCT01189266 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01189266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT03336346 — intervention group
Intervention type: DRUG
Intervention: dolutegravir
Description: HIV integrase strand transfer inhibitor used in combination ART
Study NCT03336346 — intervention group
Intervention type: DEVICE
Intervention: ENG implant
Description: Reversible contraception implant
Study NCT03336346 — intervention group
Intervention type: DRUG
Intervention: Efavirenz
Description: non-nucleoside reverse transcriptase inhibitor used in combination ART
Study NCT01298258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150mg